

Ad hoc announcement**Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share**

Korneuburg, Austria, December 5, 2024 - Marinomed Biotech AG (the "Company") announces that the Management Board has resolved today to increase the Company's share capital again by EUR 83,750 to EUR 1,778,333 by issuing 83,750 new no-par value bearer shares against cash contributions (the "Second Capital Increase"). The new shares will be issued from the authorized capital 2024 under exclusion of statutory subscription rights of existing shareholders. A report on the intended exclusion of the subscription rights of existing shareholders (the "Report") was published on the Company's website from November 28, 2024 onwards, and on the electronic announcement and information platform of the Federal Government of Austria ("EVI") on November 28, 2024. The issue price per new share is EUR 8 so that the total issue price amounts to EUR 670,000. The required Supervisory Board resolution for the Second Capital Increase under exclusion of statutory subscription rights can be passed no earlier than two weeks after publication of the Report. The Company had already provided information on a possible second capital increase in ad hoc announcements of September 2, September 15, September 18 and November 27, 2024.

All 83,750 new shares have been subscribed by a total of nine individually approached investors at these issue terms and conditions.

+++ End of ad-hoc announcement +++

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a growing development pipeline and globally marketed therapeutics. The Company develops innovative patent-protected products in the therapeutic areas immunology and virology based on the platform Marinosolv® and the virus-blocking activity of Carragelose®. The Marinosolv® technology improves the solubility and bioavailability of hardly soluble compounds and is used to develop new therapeutics for autoreactive immune disorders. The virology segment includes Carragelose®-based over-the-counter (OTC) products to prevent and treat respiratory viral infections that are partnered in more than 40 countries. The Company is headquartered in Korneuburg, Austria, and is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For further information, please visit: <https://www.marinomed.com>

For further inquiries contact:**Marinomed Biotech AG****PR: Lucia Ziegler**

T: +43 2262 90300 158

E-Mail: pr@marinomed.comE-Mail: ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as "anticipate," "believe", "estimate", "expect", "intend", "plan", "project" and "target". Forward-looking statements are only valid as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statements contained in this press release whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are registered trademarks of Marinomed Biotech AG. These trademarks may be owned or licensed in select locations only.